Strategic asset sale Wesana Health recently divested its SANA-013 assets to Lucy Scientific Discovery Inc., indicating a potential opportunity to approach the acquiring company or counterparties for follow-on collaborations in psychedelic-based mental health therapies.

M&A / partnership The acquisition activity around Wesana Health suggests a market momentum for psychedelics in mental health and a potential entry point to engage with Lucy Scientific Discovery Inc. or similar buyers for collaboration, licensing, or co-development deals.

Traumatic brain injury focus Wesana’s historical emphasis on traumatic brain injury (TBI) and BrainStorm Lab collaboration with the University of South Carolina indicates a pipeline and talent network around neuropsychiatric conditions, presenting opportunities for contract research, clinical trial partnerships, or research outsourcing.

Early-stage revenue With sub $1M revenue and $17M funding, there may be demand for cost-effective, scalable software, data analytics, or clinical operations services to support early-stage drug development and regulatory filing activities.

Industry alignment Industry peers in psychedelics, mental health, and wellness show sizable venture and commercialization activity; connecting Wesana with CROs, GMP manufacturers, and digital health platforms could accelerate market entry and broaden distribution channels for psychedelic therapies.